154 related articles for article (PubMed ID: 17154099)
1. [Graves' disease and bone metabolism].
Sato K
Nihon Rinsho; 2006 Dec; 64(12):2317-22. PubMed ID: 17154099
[TBL] [Abstract][Full Text] [Related]
2. [Osteoporosis treatment in patients with hyperthyroidism].
Saito J; Nishikawa T
Nihon Rinsho; 2009 May; 67(5):1011-6. PubMed ID: 19432125
[TBL] [Abstract][Full Text] [Related]
3. Bone turnover and the osteoprotegerin-RANKL pathway in tumor-induced osteomalacia: a longitudinal study of five cases.
Rendina D; De Filippo G; Tauchmanovà L; Insabato L; Muscariello R; Gianfrancesco F; Esposito T; Cioffi M; Colao A; Strazzullo P; Mossetti G
Calcif Tissue Int; 2009 Oct; 85(4):293-300. PubMed ID: 19763378
[TBL] [Abstract][Full Text] [Related]
4. Targeted overexpression of G protein-coupled receptor kinase-2 in osteoblasts promotes bone loss.
Wang L; Liu S; Quarles LD; Spurney RF
Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E826-34. PubMed ID: 15585587
[TBL] [Abstract][Full Text] [Related]
5. Fish liver oil and propolis as protective natural products against the effect of the anti-epileptic drug valproate on immunological markers of bone formation in rats.
Elwakkad AS; El Elshamy KA; Sibaii H
Epilepsy Res; 2008 Jul; 80(1):47-56. PubMed ID: 18455911
[TBL] [Abstract][Full Text] [Related]
6. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
Bashir A; Mak YT; Sankaralingam S; Cheung J; McGowan NW; Grigoriadis AE; Fogelman I; Hampson G
Steroids; 2005 Dec; 70(13):847-55. PubMed ID: 16005483
[TBL] [Abstract][Full Text] [Related]
7. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio.
Seriwatanachai D; Thongchote K; Charoenphandhu N; Pandaranandaka J; Tudpor K; Teerapornpuntakit J; Suthiphongchai T; Krishnamra N
Bone; 2008 Mar; 42(3):535-46. PubMed ID: 18166509
[TBL] [Abstract][Full Text] [Related]
8. [Melatonin and bone status].
Ostrowska Z; Wołkowska-Pokrywa K; Kos-Kudła B; Swietochowska E; Marek B; Kajdaniuk D
Pol Merkur Lekarski; 2006 Oct; 21(124):389-93. PubMed ID: 17205785
[TBL] [Abstract][Full Text] [Related]
9. Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemicals markers in patients with recent spinal cord injury.
Maïmoun L; Couret I; Mariano-Goulart D; Dupuy AM; Micallef JP; Peruchon E; Ohanna F; Cristol JP; Rossi M; Leroux JL
Calcif Tissue Int; 2005 Jun; 76(6):404-11. PubMed ID: 15812577
[TBL] [Abstract][Full Text] [Related]
10. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
[TBL] [Abstract][Full Text] [Related]
11. Dried plum prevents bone loss in a male osteoporosis model via IGF-I and the RANK pathway.
Franklin M; Bu SY; Lerner MR; Lancaster EA; Bellmer D; Marlow D; Lightfoot SA; Arjmandi BH; Brackett DJ; Lucas EA; Smith BJ
Bone; 2006 Dec; 39(6):1331-42. PubMed ID: 16890505
[TBL] [Abstract][Full Text] [Related]
12. [Diagnosis and treatment of immobilization osteoporosis].
Inoue D
Nihon Rinsho; 2007 Nov; 65 Suppl 9():514-9. PubMed ID: 18159714
[No Abstract] [Full Text] [Related]
13. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
14. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
[TBL] [Abstract][Full Text] [Related]
15. [The OPG/RANKL/RANK system and bone resorptive disease].
Liu JZ; Ji ZL; Chen SM
Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
[TBL] [Abstract][Full Text] [Related]
16. [OPG/RANKL: role and therapeutic target in osteoporosis].
Marie P; Halbout P
Med Sci (Paris); 2008 Jan; 24(1):105-10. PubMed ID: 18198124
[TBL] [Abstract][Full Text] [Related]
17. [Osteoclastogenesis and bone resorption].
Nakamura M; Nakamichi Y; Nakamura H; Udagawa N
Nihon Rinsho; 2009 May; 67(5):889-96. PubMed ID: 19432105
[TBL] [Abstract][Full Text] [Related]
18. Markers of bone metabolism in eugonadal female patients with beta-thalassemia major.
Angelopoulos NG; Goula A; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Konstandelou E; Tolis G
Pediatr Hematol Oncol; 2007; 24(7):481-91. PubMed ID: 17786784
[TBL] [Abstract][Full Text] [Related]
19. RANKL signaling in bone physiology and cancer.
Dougall WC
Curr Opin Support Palliat Care; 2007 Dec; 1(4):317-22. PubMed ID: 18685382
[TBL] [Abstract][Full Text] [Related]
20. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B
Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
